Member Info for HotChip

The SP has a 17.4% spread right now, quickly eroding any profit to be made in the short-term. Buyer beware, you will need a big uplift to break even atm.

DYOR

You need to get yourself a decent program like SharePad; much more insight to the movement of the SP than relying on LSE IMO.

DYOR

Imagine? Why?

What do you think?

SeenRight84 - I assume you mean a disaster in terms of SP performance? That is outside of the company's control and determined by supply/demand of the stock. Given market conditions over the past 12 months, it is clear to me that external factors and the general movement of PIs out of pharma stocks have driven the SP down during this period.

IMO POLB have done everything stated in the IPO doc and more. Unfortunately, the market does not recognise this but will do so if & when the output from POLB001 is positive and results in out-licencing deal(s).

DYOR

I think CF just gets a bit carried away when he talks. And unfortunately, it can go against you/the company when things do not go as well as planned....as we have seen over the past 18 months or so.

But, there is a alot going for ORPH and given time, I think we can see the SP recovering to the late-20s but we are looking at 2-3 years from now in my view. If we get taken over, then I don't think it will be a bad thing....

DYOR

GC - Contract order book stands at over £80mln — almost three times the value of the order book during the same period FY2021. It's business already signed up, not expected to be signed up. You need to read the reports.

DYOR

I wouldn't get excited if he did buy. He has already confirmed he doesn't have deep pockets, so it will only be a small and insignificant amount in my view. Won't make any difference to the SP.

DYOR

Correction to my previous statement - should say 'proving':

"I am a little concerned that MHC are already talking about new products without *PROVING the recently launched ones first. Surely pushing existing products first must be a priority, but we shall see."

jamrock - I see nothing to suggest these products will be on sale in Boots and Superdrug, at least any time soon, so I wouldn't get your hopes up about this. The focus is on selling through Amazon at present and I assume this will remain the case until sales are proven. This may take some time and with potential new products in the pipeline for launch in Q422, I assume these will also go the Amazon way and need proven.

There is no indication in these results on sales figures post-reporting period. I assume (rightly or wrongly) that this is insignificant at present and needs time to grow. Key focus must be on marketing activity to make these products visible to consumers and target market asap, to take advantage of sales opportunities. I would like to hear more about these plans in tomorrow's meeting.

I am a little concerned that MHC are already talking about new products without providing the recently launched ones first. Surely pushing existing products first must be a priority, but we shall see.

Lots of good stuff happening though and I am optimistic about the future, but for me, I think this is a slow burner with many hurdles ahead to convince the market that the demand for these products is actually there in the medium to long term.

For me, the SP undervalues the company somewhat and I would have expected to see a value around the 3-3.5p mark at this stage.

DYOR

I have put forward about half-a-dozen questions to the company for tomorrow's results meeting - requesting more info on what milestone was not met by Nell Health and what the impact has been, director buying and share buy-backs, planned marketing activities on existing products, future plans for high-street stocking of products, future acquisitions, further funding from the market, and competition from competitors.

DYOR

Stas20 - I think you are spot-on with your summary and I echo the comments made.

DYOR

"The Directors have reconsidered the principal risks and uncertainties and have concluded that the risks published in the 2021 annual report remain appropriate, although highlight the impact that rising interest rates and supply and demand dynamics have had on global inflation rates in 2022, and that continued inflation rate increases could adversely impact the future operating and capital expenditures of the Group."

Let's not forget the inherent risks associated with rising interest rates. This could lead to a reduction in the dividend in 2023 and beyond, on top of the obvious operating and capital requirements. And of course a further depletion of the SP until we come through and out the other end of this upcoming recession.

DYOR

I get your point; I haven't moved all of my holding into cash, I've top-sliced a sizeable amount at c.28p, retaining some for serenity and Canada upside. Keeping some cash back to invest in other stocks as the market gets even more depressed over the coming weeks and months ahead. Alot of bargains out there by then.

DYOR

Let's see what the results give us this coming week and where they are apportioning their build up of cash into new products and potential acquisitions going forward. Looks promising imo.

DYOR

I would say the flight from equities more broadly is contributing heavily to the downward pressure on the SP. This, in my opinion, will continue regardless of serenity output and is felt more widely across equity markets in general - i3E is not immune to this. Moving into cash is for me a sensible option in order to have a balanced portfolio and not be too exposed to the downward pressure of the SP.

I am not sure I agree with your thoughts on the presentation, yes the slides were from Q2, but I am not sure there was a lack of enthusiasm. It was a corporate presentation to what looked like a mainly white male audience of a certain age - so it was pitched at the right level imo. If you were after jazz hands et all, I don't think you will get that from MS as this is not his style. And I don't think that approach would have come off as professional.

DYOR

Can you provide a link to the tweet please, as I cannot see this?

Longlad - not really understanding your point, can you explain? You copied this from twitter, so what is the potential issue with this if you are simply copy and pasting something on there. I guess its factually correct what you have posted?

DYOR

Looking promising at the moment :)

DYOR

Agreed, additional value needs to be created to make this an attractive proposition from what it is today. A growing company, but very small compared to its peers.

DYOR